Literature DB >> 24663289

A prediction model for 5-year cardiac mortality in patients with chronic heart failure using ¹²³I-metaiodobenzylguanidine imaging.

Kenichi Nakajima1, Tomoaki Nakata, Takahisa Yamada, Shohei Yamashina, Mitsuru Momose, Shu Kasama, Toshiki Matsui, Shinro Matsuo, Mark I Travin, Arnold F Jacobson.   

Abstract

PURPOSE: Prediction of mortality risk is important in the management of chronic heart failure (CHF). The aim of this study was to create a prediction model for 5-year cardiac death including assessment of cardiac sympathetic innervation using data from a multicenter cohort study in Japan.
METHODS: The original pooled database consisted of cohort studies from six sites in Japan. A total of 933 CHF patients who underwent (123)I-metaiodobenzylguanidine (MIBG) imaging and whose 5-year outcomes were known were selected from this database. The late MIBG heart-to-mediastinum ratio (HMR) was used for quantification of cardiac uptake. Cox proportional hazard and logistic regression analyses were used to select appropriate variables for predicting 5-year cardiac mortality. The formula for predicting 5-year mortality was created using a logistic regression model.
RESULTS: During the 5-year follow-up, 205 patients (22 %) died of a cardiac event including heart failure death, sudden cardiac death and fatal acute myocardial infarction (64 %, 30 % and 6 %, respectively). Multivariate logistic analysis selected four parameters, including New York Heart Association (NYHA) functional class, age, gender and left ventricular ejection fraction, without HMR (model 1) and five parameters with the addition of HMR (model 2). The net reclassification improvement analysis for all subjects was 13.8 % (p < 0.0001) by including HMR and its inclusion was most effective in the downward reclassification of low-risk patients. Nomograms for predicting 5-year cardiac mortality were created from the five-parameter regression model.
CONCLUSION: Cardiac MIBG imaging had a significant additive value for predicting cardiac mortality. The prediction formula and nomograms can be used for risk stratifying in patients with CHF.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24663289      PMCID: PMC4122818          DOI: 10.1007/s00259-014-2759-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  28 in total

1.  Evaluation of beta-blocker therapy in patients with dilated cardiomyopathy--Clinical meaning of iodine 123-metaiodobenzylguanidine myocardial single-photon emission computed tomography.

Authors:  J Yamazaki; H Muto; T Kabano; S Yamashina; S Nanjo; A Inoue
Journal:  Am Heart J       Date:  2001-04       Impact factor: 4.749

2.  Cardiac event risk in Japanese subjects estimated using gated myocardial perfusion imaging, in conjunction with diabetes mellitus and chronic kidney disease.

Authors:  Kenichi Nakajima; Shinro Matsuo; Chio Okuyama; Tsuguru Hatta; Kazumasa Tsukamoto; Shigeyuki Nishimura; Akira Yamashina; Hideo Kusuoka; Tsunehiko Nishimura
Journal:  Circ J       Date:  2011-11-19       Impact factor: 2.993

3.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  J Am Coll Cardiol       Date:  2013-06-05       Impact factor: 24.094

4.  Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death.

Authors:  T Wakabayashi; T Nakata; A Hashimoto; S Yuda; K Tsuchihashi; M I Travin; K Shimamoto
Journal:  J Nucl Med       Date:  2001-12       Impact factor: 10.057

5.  Usefulness of cardiac iodine-123 meta-iodobenzylguanidine imaging to improve prognostic power of Seattle heart failure model in patients with chronic heart failure.

Authors:  Yuki Kuramoto; Takahisa Yamada; Shunsuke Tamaki; Yuji Okuyama; Takashi Morita; Yoshio Furukawa; Koji Tanaka; Yusuke Iwasaki; Taku Yasui; Hiromichi Ueda; Takeshi Okada; Masato Kawasaki; Wayne C Levy; Issei Komuro; Masatake Fukunami
Journal:  Am J Cardiol       Date:  2011-02-23       Impact factor: 2.778

6.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators.

Authors:  A J Moss; W J Hall; D S Cannom; J P Daubert; S L Higgins; H Klein; J H Levine; S Saksena; A L Waldo; D Wilber; M W Brown; M Heo
Journal:  N Engl J Med       Date:  1996-12-26       Impact factor: 91.245

7.  Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion.

Authors:  Shunsuke Tamaki; Takahisa Yamada; Yuji Okuyama; Takashi Morita; Shoji Sanada; Yasumasa Tsukamoto; Masaharu Masuda; Keiji Okuda; Yusuke Iwasaki; Taku Yasui; Masatsugu Hori; Masatake Fukunami
Journal:  J Am Coll Cardiol       Date:  2009-02-03       Impact factor: 24.094

8.  The Seattle Heart Failure Model: prediction of survival in heart failure.

Authors:  Wayne C Levy; Dariush Mozaffarian; David T Linker; Santosh C Sutradhar; Stefan D Anker; Anne B Cropp; Inder Anand; Aldo Maggioni; Paul Burton; Mark D Sullivan; Bertram Pitt; Philip A Poole-Wilson; Douglas L Mann; Milton Packer
Journal:  Circulation       Date:  2006-03-13       Impact factor: 29.690

9.  Prognostic value of repeated 123I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments--comparison with neurohumoral factors.

Authors:  Toshiki Matsui; Takayoshi Tsutamoto; Keiko Maeda; Junya Kusukawa; Masashiko Kinoshita
Journal:  Circ J       Date:  2002-06       Impact factor: 2.993

10.  A pooled analysis of multicenter cohort studies of (123)I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure.

Authors:  Tomoaki Nakata; Kenichi Nakajima; Shohei Yamashina; Takahisa Yamada; Mitsuru Momose; Shu Kasama; Toshiki Matsui; Shinro Matsuo; Mark I Travin; Arnold F Jacobson
Journal:  JACC Cardiovasc Imaging       Date:  2013-07
View more
  22 in total

1.  The time has come to standardize (123)I-MIBG heart-to-mediastinum ratios including planar and SPECT methods.

Authors:  Kenichi Nakajima; Koichi Okuda; Shinro Matsuo; Denis Agostini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-23       Impact factor: 9.236

2.  Quantification of I-123-meta-iodobenzylguanidine heart-to-mediastinum ratios: not so simple after all.

Authors:  Piotr J Slomka; Puja K Mehta; Guido Germano; Daniel S Berman
Journal:  J Nucl Cardiol       Date:  2014-07-09       Impact factor: 5.952

Review 3.  Cardiac molecular imaging to track left ventricular remodeling in heart failure.

Authors:  Jamshid Shirani; Amitoj Singh; Sahil Agrawal; Vasken Dilsizian
Journal:  J Nucl Cardiol       Date:  2016-08-01       Impact factor: 5.952

4.  Iodine-123 metaiodobenzylguanidine scintigraphy for the assessment of cardiac sympathetic innervation and the relationship with cardiac autonomic function in healthy adults using standardized methods.

Authors:  Omar Asghar; Parthiban Arumugam; Ian Armstrong; Simon Ray; Matthias Schmitt; Rayaz A Malik
Journal:  Nucl Med Commun       Date:  2017-01       Impact factor: 1.690

5.  Influence of ROI definition on the heart-to-mediastinum ratio in planar 123I-MIBG imaging.

Authors:  Christiane Klene; Christiane Jungen; Koichi Okuda; Yuske Kobayashi; Annabelle Helberg; Janos Mester; Christian Meyer; Kenichi Nakajima
Journal:  J Nucl Cardiol       Date:  2016-11-01       Impact factor: 5.952

Review 6.  Prognostic Significance of Imaging Myocardial Sympathetic Innervation.

Authors:  Saurabh Malhotra; Stanley F Fernandez; James A Fallavollita; John M Canty
Journal:  Curr Cardiol Rep       Date:  2015-08       Impact factor: 2.931

Review 7.  Cardiac 123I-mIBG Imaging in Heart Failure.

Authors:  Derk O Verschure; Kenichi Nakajima; Hein J Verberne
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-25

Review 8.  (123)I-Meta-iodobenzylguanidine Sympathetic Imaging: Standardization and Application to Neurological Diseases.

Authors:  Kenichi Nakajima; Masahito Yamada
Journal:  Chonnam Med J       Date:  2016-09-23

9.  Impact of aging on cardiac sympathetic innervation measured by 123I-mIBG imaging in patients with systolic heart failure.

Authors:  Giuseppe Rengo; Gennaro Pagano; Dino Franco Vitale; Roberto Formisano; Klara Komici; Laura Petraglia; Valentina Parisi; Grazia Daniela Femminella; Claudio de Lucia; Stefania Paolillo; Alessandro Cannavo; Emilio Attena; Teresa Pellegrino; Santo Dellegrottaglie; Alessia Memmi; Bruno Trimarco; Alberto Cuocolo; Pasquale Perrone Filardi; Dario Leosco; Nicola Ferrara
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-10       Impact factor: 9.236

10.  Prognostic usefulness of planar 123I-MIBG scintigraphic images of myocardial sympathetic innervation in congestive heart failure: Follow-Up data from ADMIRE-HF.

Authors:  Denis Agostini; Karthikeyan Ananthasubramaniam; Harish Chandna; Lars Friberg; Andrew Hudnut; Michael Koren; Michael I Miyamoto; Roxy Senior; Mahesh Shah; Mark I Travin; Jürgen Vom Dahl; Kun Chen; Wayne C Levy
Journal:  J Nucl Cardiol       Date:  2019-08-29       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.